ERBB2 and breast cancer: Recent advances in molecular technologies have facilitated breast cancer research, allowing researchers and physicians to use biomarkers expressed by cancerous cells to categorize this pathology into four distinct groups—luminal A, luminal B, HER2-positive and TNBC.